Answers are grounded in this paper and cite their sources.
Chronic diseases are still treated largely with interventions that are constitutive, intermittently administered and poorly aligned with real-time physiology. Synthetic biology is changing this paradigm by treating gene circuits as programmable genetic software that can be deployed across cellular therapeutic hardware spanning from prokaryotic to eukaryotic systems, including probiotic cells, designer cells, immune cells and stem‑cell‑derived platforms. In this framework, engineered systems can sense disease-associated signals, compute them through synthetic or repurposed transduction pathways and adjust therapeutic output to maintain physiological variables within a desired range. Closed-loop therapeutics therefore begin to merge diagnosis, treatment and prevention within the same living platform. Across metabolism, inflammation, infection, cardiovascular regulation and cancer, early mammalian systems show that endogenous sensing, intracellular computation and therapeutic actuation can be combined in clinically relevant architectures. The emerging concept of setpoint medicine captures the clinical ambition of these systems: not simply to deliver a dose, but to keep physiology within an interpretable and therapeutically desirable range. Realizing this vision will require durable and modular control circuits, hardware-aware delivery strategies, interpretable safety frameworks, controller-style performance metrics and increasingly AI-assisted design, calibration and oversight. If these challenges can be met, the future of therapy may be defined less by intermittent dosing than by the continuous control of physiology.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: